Spectroscopic observations of β-eudesmol binding to human cytochrome P450 isoforms 3A4 and 1A2, but not to isoforms 2C9, 2C19, and 2D6

References

• Baas BJ, Denisov IG, Sligar SG. 2004. Homotropic cooperativity of monomeric cytochrome P450 3A4 in a nanoscale native bilayer environment. Arch Biochem Biophys. 430(2):218–228.
   PubMed Web of Science ®Google Scholar
• Castrignanò S, D’Avino S, Di Nardo G, Catucci G, Sadeghi SJ, Gilardi G. 2018. Modulation of the interaction between human P450 3A4 and B. megaterium reductase via engineered loops. Biochim Biophys Acta Proteins Proteom. 1866(1):116–125.
   PubMed Web of Science ®Google Scholar
• Cohen SN, Chang AC, Hsu L. 1972. Nonchromosomal antibiotic resistance in bacteria: genetic transformation of Escherichia coli by R-factor DNA. Proc Natl Acad Sci USA. 69(8):2110–2114.
   PubMed Web of Science ®Google Scholar
• Di Nardo G, Gilardi G. 2020. Nattural compounds as pharmaceuticals: the key role of cytochromes P450 reactivity. Trends Biochem Sci. 45(6):511–525.
   PubMed Web of Science ®Google Scholar
• Farooq Y, Roberts GC. 2010. Kinetics of electron transfer between NADPH-cytochrome P450 reductase and cytochrome P450 3A4. Biochem J. 432(3):485–493.
   PubMed Web of Science ®Google Scholar
• Gillam EM. 1998. Human cytochrome P450 enzymes expressed in bacteria: reagents to probe molecular interactions in toxicology. Clin Exp Pharmacol Physiol. 25(11):877–886.
   PubMed Web of Science ®Google Scholar
• Gillam EM, Baba T, Kim BR, Ohmori S, Guengerich FP. 1993. Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme. Arch Biochem Biophys. 305(1):123–131.
   PubMed Web of Science ®Google Scholar
• Gillam EM, Guo Z, Martin MV, Jenkins CM, Guengerich FP. 1995. Expression of cytochrome P450 2D6 in Escherichia coli, purification, and spectral and catalytic characterization. Arch Biochem Biophys. 319(2):540–550.
   PubMed Web of Science ®Google Scholar
• Godamudunage MP, Grech AM, Scott EE. 2018. Comparison of antifungal azole interactions with adult cytochrome P450 3A4 versus neonatal cytochrome P450 3A7. Drug Metab Dispos. 46(9):1329–1337.
   PubMed Web of Science ®Google Scholar
• Guengerich FP. 2022. Inhibition of cytochrome P450 enzymes by drugs-molecular basis and practical applications. Biomol Ther (Seoul). 30(1):1–18.
   PubMed Web of Science ®Google Scholar
• Harlow GR, Halpert JR. 1998. Analysis of human cytochrome P450 3A4 cooperativity: construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics. Proc Natl Acad Sci USA. 95(12):6636–6641.
   PubMed Web of Science ®Google Scholar
• Hosea NA, Miller GP, Guengerich FP. 2000. Elucidation of distinct ligand binding sites for cytochrome P450 3A4. Biochemistry. 39(20):5929–5939.
   PubMed Web of Science ®Google Scholar
• Isin EM, Guengerich FP. 2008. Substrate binding to cytochromes P450. Anal Bioanal Chem. 392(6):1019–1030.
   PubMed Web of Science ®Google Scholar
• Jefcoate CR. 1978. Measurement of substrate and inhibitor binding to microsomal cytochrome P-450 by optical-difference spectroscopy. Methods Enzymol. 52:258–279.
   PubMedGoogle Scholar
• Johnston WA, Gillam EM. 2013. Measurement of P450 difference spectra using intact cells. Methods Mol Biol. 987:189–204.
   PubMedGoogle Scholar
• Johnston WA, Huang W, De Voss JJ, Hayes MA, Gillam EM. 2008. Quantitative whole-cell cytochrome P450 measurement suitable for high-throughput application. J Biomol Screen. 13(2):135–141.
   PubMedGoogle Scholar
• Johnston WA, Hunter DJ, Noble CJ, Hanson GR, Stok JE, Hayes MA, De Voss JJ, Gillam EM. 2011. Cytochrome P450 is present in both ferrous and ferric forms in the resting state within intact Escherichia coli and hepatocytes. J Biol Chem. 286(47):40750–40759.
   PubMed Web of Science ®Google Scholar
• Kim S, Chen J, Cheng T, Gindulyte A, He J, He S, Li Q, Shoemaker BA, Thiessen PA, Yu B, et al. 2021. PubChem in 2021: new data content and improved web interfaces. Nucleic Acids Res. 849(D1):D1388–D1395.
   PubMed Web of Science ®Google Scholar
• Koonrungsesomboon N, Na-Bangchang K, Karbwang J. 2014. Therapeutic potential and pharmacological activities of Atractylodes lancea (Thunb.) DC. Asian Pac J Trop Med. 7(6):421–428.
   PubMed Web of Science ®Google Scholar
• Kotawong K, Chaijaroenkul W, Roytrakul S, Phaonakrop N, Na-Bangchang K. 2020. Proteomics analysis for identification of potential cell signaling pathways and protein targets of actions of atractylodin and β-eudesmol against cholangiocarcinoma. Asian Pac J Cancer Prev. 21(3):621–628.
   PubMedGoogle Scholar
• Krest CM, Onderko EL, Yosca TH, Calixto JC, Karp RF, Livada J, Rittle J, Green MT. 2013. Reactive intermediates in cytochrome p450 catalysis. J Biol Chem. 288(24):17074–17081.
   PubMed Web of Science ®Google Scholar
• Lewis DF, Ito Y. 2010. Human CYPs involved in drug metabolism: structures, substrates and binding affinities. Expert Opin Drug Metab Toxicol. 6(6):661–674.
   PubMed Web of Science ®Google Scholar
• Locuson CW, Hutzler JM, Tracy TS. 2007. Visible spectra of type II cytochrome P450-drug complexes: evidence that “incomplete” heme coordination is common. Drug Metab Dispos. 35(4):614–622.
   PubMed Web of Science ®Google Scholar
• Luthra A, Denisov IG, Sligar SG. 2011. Spectroscopic features of cytochrome P450 reaction intermediates. Arch Biochem Biophys. 507(1):26–35.
   PubMed Web of Science ®Google Scholar
• Mathema VB, Chaijaroenkul W, Karbwang J, Na-Bangchang K. 2017. Growth inhibitory effect of β-eudesmol on cholangiocarcinoma cells and its potential suppressive effect on heme oxygenase-1 production, STAT1/3 activation, and NF-κB downregulation. Clin Exp Pharmacol Physiol. 44(11):1145–1154.
   PubMed Web of Science ®Google Scholar
• Na-Bangchang K, Kulma I, Plengsuriyakarn T, Tharavanij T, Kotawng K, Chemung A, Muhamad N, Karbwang J. 2021. Phase I clinical trial to evaluate the safety and pharmacokinetics of capsule formulation of the standardized extract of Atractylodes lancea. J Tradit Complement Med. 11(4):343–355.
   PubMedGoogle Scholar
• Na-Bangchang K, Plengsuriyakarn T, Karbwang J. 2017. Research and development of Atractylodes lancea (Thunb) DC. as a promising candidate for cholangiocarcinoma chemotherapeutics. Evid Based Complement Alternat Med. 2017:5929234. Epub 2017 Nov 14.
   PubMed Web of Science ®Google Scholar
• Narahara C, Saeheng T, Chaijaroenkul W, Dumre SP, Na-Bangchang K, Karbwang J. 2020. β-Eudesmol induces the expression of apoptosis pathway proteins in cholangiocarcinoma cell lines. J Res Med Sci. 25 (25):7.
   PubMed Web of Science ®Google Scholar
• Nishihara K, Kanemori M, Kitagawa M, Yanagi H, Yura T. 1998. Chaperone coexpression plasmids: differential and synergistic roles of DnaK-DnaJ-GrpE and GroEL-GroES in assisting folding of an allergen of Japanese cedar pollen, Cryj2, in Escherichia coli. Appl Environ Microbiol. 64(5):1694–1699.
   PubMed Web of Science ®Google Scholar
• Ohara K, Fukuda T, Ishida Y, Takahashi C, Ohya R, Katayama M, Uchida K, Tominaga M, Nagai K. 2017. β-Eudesmol, an oxygenized sesquiterpene, stimulates appetite via TRPA1 and the autonomic nervous system. Sci Rep. 7(1):15785.
   PubMed Web of Science ®Google Scholar
• Omura T, Sato R. 1964. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem. 239:2370–2378.
   PubMed Web of Science ®Google Scholar
• Parikh A, Gillam EM, Guengerich FP. 1997. Drug metabolism by Escherichia coli expressing human cytochromes P450. Nat Biotechnol. 15(8):784–788.
   PubMed Web of Science ®Google Scholar
• Preissner SC, Hoffmann MF, Preissner R, Dunkel M, Gewiess A, Preissner S. 2013. Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy. PLoS One. 8(12):e82562.
   PubMed Web of Science ®Google Scholar
• Ri website. 2002–2021. London: the royal institution of Great Britain. [accessed 2021 Dec 02]. https://www.rigb.org/whats-on/events-2017/november/public-bonfires-with-a-bang.
   Google Scholar
• Richardson TH, Jung F, Griffin KJ, Wester M, Raucy JL, Kemper B, Bornheim LM, Hassett C, Omiecinski CJ, Johnson EF. 1995. A universal approach to the expression of human and rabbit cytochrome P450s of the 2C subfamily in Escherichia coli. Arch Biochem Biophys. 323(1):87–96.
   PubMed Web of Science ®Google Scholar
• Sandhu P, Baba T, Guengerich FP. 1993. Expression of modified cytochrome P450 2C10 (2C9) in Escherichia coli, purification, and reconstitution of catalytic activity. Arch Biochem Biophys. 1306(2):443–450.
   PubMed Web of Science ®Google Scholar
• Sandhu P, Guo Z, Baba T, Martin MV, Tukey RH, Guengerich FP. 1994. Expression of modified human cytochrome P450 1A2 in Escherichia coli: stabilization, purification, spectral characterization, and catalytic activities of the enzyme. Arch Biochem Biophys. 5309(1):168–177.
   PubMed Web of Science ®Google Scholar
• Satoh K, Nagai F, Ushiyama K, Yasuda I, Akiyama K, Kano I. 1992. Inhibition of Na+,K(+)-ATPase activity by beta-eudesmol, a major component of Atractylodis lancea rhizoma, due to the interaction with enzyme in the Na.E1 state. Biochem Pharmacol. 44(2):373–378.
   PubMed Web of Science ®Google Scholar
• Sevrioukova IF. 2017. High-level production and properties of the cysteine-depleted cytochrome P450 3A4. Biochemistry. 56(24):3058–3067.
   PubMed Web of Science ®Google Scholar
• Sevrioukova IF. 2019. Structural insights into the interaction of cytochrome P450 3A4 with suicide substrates: mibefradil, azamulin and 6',7'-Dihydroxybergamottin. Int J Mol Sci. 20(17):4245.
   PubMed Web of Science ®Google Scholar
• Sevrioukova IF, Poulos TL. 2017. Structural basis for regiospecific midazolam oxidation by human cytochrome P450 3A4. Proc Natl Acad Sci USA. 114(3):486–491.
   PubMed Web of Science ®Google Scholar
• Sohl CD, Cheng Q, Guengerich FP. 2009. Chromatographic assays of drug oxidation by human cytochrome P450 3A4. Nat Protoc. 4(9):1252–1257.
   PubMed Web of Science ®Google Scholar
• Špičáková A, Bazgier V, Skálová L, Otyepka M, Anzenbacher P. 2019. Beta-caryophyllene oxide and trans-nerolidol affect enzyme activity of CYP3A4 - in vitro and in silico studies. Physiol Res. 68(1):S51–S58.
   PubMed Web of Science ®Google Scholar
• Srijiwangsa P, Ponnikorn S, Na-Bangchang K. 2018. Effect of β-Eudesmol on NQO1 suppression-enhanced sensitivity of cholangiocarcinoma cells to chemotherapeutic agents. BMC Pharmacol Toxicol. 19(1):32.
   PubMed Web of Science ®Google Scholar
• Sumsakul W, Mahavorasirikul W, Na-Bangchang K. 2015. Inhibitory activities of Thai medicinal plants with promising activities against Malaria and cholangiocarcinoma on human cytochrome P450. Phytother Res. 29(12):1926–1933.
   PubMed Web of Science ®Google Scholar
• Thellamurege N, Hirao H. 2013. Water complexes of cytochrome P450: insights from energy decomposition analysis. Molecules. 18(6):6782–6791.
   PubMed Web of Science ®Google Scholar
• Traylor MJ, Baek JM, Richards KE, Fusetto R, Huang W, Josh P, Chen Z, Bollapragada P, O'Hair RAJ, Batterham P, et al. 2017. Recombinant expression and characterization of Lucilia cuprina CYP6G3: Activity and binding properties toward multiple pesticides. Insect Biochem Mol Biol. 90:14–22.
   PubMed Web of Science ®Google Scholar
• Tsusaka T, Makino B, Ohsawa R, Ezura H. 2020. Evaluation of heritability of β-eudesmol/hinesol content ratio in Atractylodes lancea De Candolle. Hereditas. 157(1):7.
   PubMed Web of Science ®Google Scholar
• Varma KR, Jain TC, Bhattacharyya SC. 1962. Terpenoids—XXXIV: structure and stereochemistry of zingiberol and juniper camphor. Tetrahedron. 18(8):979–984.
   Web of Science ®Google Scholar
• Wiesenburg DA, Guinasso NL. Jr. 1979. Equilibrium solubilities of methane, carbon monoxide, and hydrogen in water and sea water. J Chem Eng Data. 24(4):356–360.
   Web of Science ®Google Scholar
• Yun CH, Yim SK, Kim DH, Ahn T. 2006. Functional expression of human cytochrome P450 enzymes in Escherichia coli. Curr Drug Metab. 7(4):411–429.
   PubMed Web of Science ®Google Scholar